16 min
New Celiac Treatment Passes Phase 2 Clinical Trial The Gluten-Free Guide
-
- Nutrition
Do we have a new drug for celiac disease? Results of a new phase 2 clinical trial using technology developed at Northwestern university showed that it is possible to induce immune tolerance to gluten in individuals with celiac disease. The researchers suggest that their findings may pave the way for treated celiac patients to eventually tolerate gluten in their diet. As we are writing these these words we can hear our listener around the world cheering for joy that there may be a magic pill to take that will allow them to eat gluten. But is that really the case?
To help us better understand what this new drug is and how it might help patients with celiac disease, we have Dr. Jocelyn Silvester from Boston Children’s Hospital in the studio. Dr. Silvester is a leading celiac disease research in the United States and Canada and one of our favorite podcast guests!
Thank you to the Walter and Jean Boek Global Autoimmune Institute for their ongoing support to make this podcast possible.
Do we have a new drug for celiac disease? Results of a new phase 2 clinical trial using technology developed at Northwestern university showed that it is possible to induce immune tolerance to gluten in individuals with celiac disease. The researchers suggest that their findings may pave the way for treated celiac patients to eventually tolerate gluten in their diet. As we are writing these these words we can hear our listener around the world cheering for joy that there may be a magic pill to take that will allow them to eat gluten. But is that really the case?
To help us better understand what this new drug is and how it might help patients with celiac disease, we have Dr. Jocelyn Silvester from Boston Children’s Hospital in the studio. Dr. Silvester is a leading celiac disease research in the United States and Canada and one of our favorite podcast guests!
Thank you to the Walter and Jean Boek Global Autoimmune Institute for their ongoing support to make this podcast possible.
16 min